Hollow MIL-125 Nanoparticles Loading Doxorubicin Prodrug and 3-Methyladenine for Reversal of Tumor Multidrug Resistance
Source abstract
Abstract
Multidrug resistance (MDR) is a key factor in chemotherapy failure and tumor recurrence. The inhibition of drug efflux and autophagy play important roles in MDR therapy. Herein, a multifunctional delivery system (HA-MIL-125@DVMA) was prepared for synergistically reverse tumor MDR. Tumor-targeted hollow MIL-125-Ti nanoparticles were used to load the doxorubicin–vitamin E succinate (DV) prodrug and 3-methyladenine (3-MA) to enhance reverse MDR effects. The pH-sensitive DV can kill tumor cells and inhibit P-gp-mediated drug efflux, and 3-MA can inhibit autophagy. HA-MIL-125@DVMA had uniformly distributed particle size and high drug-load content. The nanoparticles could effectively release the drugs into tumor microenvironment due to the rapid hydrazone bond-breaking under low pH conditions, resulting in a high cumulative release rate. In in vitro cellular experiments, the accumulation of HA-MIL-125@DVMA and HA-MIL-125@DV in MCF-7/ADR cells was significantly higher than that in the control groups. Moreover, the nanoparticles significantly inhibited drug efflux in the cells, ensuring the accumulation of the drugs in cell cytoplasm and causing drug-resistant cells’ death. Importantly, HA-MIL-125@DVMA effectively inhibited tumor growth without changes in body weight in tumor-bearing mice. In summary, the combination of the acid-sensitive prodrug DV and autophagy inhibitor 3-MA in a HA-MIL-125 nanocarrier can enhance the antitumor effect and reverse tumor MDR.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · Metal-Organic Frameworks: Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Thyroid and Breast Surgery, Affiliated Hospital of Jiangnan University, Wuxi 214122, China
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China
Funding
National Key Research and Development Program of China · Wuxi Science and Technology Development Fund Project
References (52)
Show source-provided references
1. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells10.1016/j.canlet.2018.10.007 ↗
2. MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells10.1016/j.biopha.2018.10.169 ↗
3. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo10.1016/j.taap.2018.01.015 ↗
4. Park, J.Y., Lee, G.H., Yoo, K.H., and Khang, D. (2023). Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs. J. Nanobiotechnol., 21.10.1186/s12951-023-01768-8 ↗
5. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma10.2174/0929867325666180105103637 ↗
6. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies10.1016/j.drup.2016.05.001 ↗
7. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR10.1016/j.biopha.2018.02.038 ↗
8. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives10.2174/15680096113139990076 ↗
9. Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
10. Three decades of P-gp inhibitors: Skimming through several generations and scaffolds10.2174/092986712800167392 ↗
11. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update10.1208/s12248-014-9668-6 ↗
12. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation10.1016/j.biopha.2018.02.130 ↗
13. Modulation of P-glycoprotein efflux pump: Induction and activation as a therapeutic strategy10.1016/j.pharmthera.2014.11.013 ↗
14. P-glycoprotein ATPase activity requires lipids to activate a switch at the first transmission interface10.1016/j.bbrc.2016.02.124 ↗
15. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense10.1016/j.taap.2004.10.012 ↗
16. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma10.1016/j.carbpol.2018.05.090 ↗
17. Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer10.1021/mp400778r ↗
18. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models10.1016/j.drup.2023.100956 ↗
19. Understanding the implications of co-delivering therapeutic agents in a nanocarrier to combat multidrug resistance (MDR) in breast cancer10.1016/j.jddst.2021.102405 ↗
20. Nanocarrier based on the assembly of protein and antisense oligonucleotide to combat multidrug resistance in tumor cells10.1007/s11426-017-9108-5 ↗
21. Gold nanorods together with HSP inhibitor-VER-155008 micelles for colon cancer mild-temperature photothermal therapy10.1016/j.apsb.2018.05.011 ↗
22. Triple Signal Amplification Strategy for Ultrasensitive Determination of miRNA Based on Duplex Specific Nuclease and Bridge DNA-Gold Nanoparticles10.1021/acs.analchem.7b05447 ↗
23. Monodisperse Cu/Cu2O@C core–shell nanocomposite supported on rGO layers as an efficient catalyst derived from a Cu-based MOF/GO structure10.1039/C8NR04475A ↗
24. Methane adsorption on graphene from first principles including dispersion interaction10.1016/j.susc.2011.01.012 ↗
25. Graphene oxide as an optimal candidate material for methane storage10.1063/1.4927141 ↗
26. MOF-GO Hybrid Nanocomposite Adsorbents for Methane Storage10.1021/acs.iecr.8b03638 ↗
27. MOF–Graphite Oxide Composites: Combining the Uniqueness of Graphene Layers and Metal–Organic Frameworks10.1002/adma.200901581 ↗
28. Reactive Adsorption of Ammonia on Cu-Based MOF/Graphene Composites10.1021/la1021092 ↗
29. Enhanced Adsorption of Ammonia on Metal-Organic Framework/Graphite Oxide Composites: Analysis of Surface Interactions10.1002/adfm.200900880 ↗
30. Improving the hydrogen selectivity of graphene oxide membranes by reducing non-selective pores with intergrown ZIF-8 crystals10.1039/C6CC02013E ↗
31. Preparation of nanoporous graphene oxide by nanocrystal-masked etching: Toward a nacre-mimetic metal–organic framework molecular sieving membrane10.1039/C7TA00927E ↗
32. Encapsulation of liquid metal nanoparticles inside metal–organic frameworks for hydrogel-integrated dual functional biotherapy10.1016/j.cej.2023.141302 ↗
33. Simple method for fabrication of metal-organic framework within a carboxymethylcellulose/graphene quantum dots matrix as a carrier for anticancer drug10.1016/j.ijbiomac.2020.08.121 ↗
34. Dariush, T.S., Janet, S., and Aliakbar, T. (2017). Application of Metal-Organic Framework Nano-MIL-100(Fe) for Sustainable Release of Doxycycline and Tetracycline. Nanomaterials, 7.10.3390/nano7080215 ↗
35. The impact of MOFs in pH-dependent drug delivery systems: Progress in the last decade10.1039/D2DT00994C ↗
36. Photoactive MOF-Derived Bimetallic Silver and Cobalt Nanocomposite with Enhanced Antibacterial Activity10.1021/acsami.3c01529 ↗
37. Chemodynamic and Photothermal Combination Therapy Based on Dual-Modified Metal-Organic Framework for Inducing Tumor Ferroptosis/Pyroptosis10.1021/acsami.2c00574 ↗
38. A Self-Driven Bioreactor Based on Bacterium-Metal-Organic Framework Biohybrids for Boosting Chemotherapy via Lactate Catabolism10.1021/acsnano.1c06123 ↗
39. Lin, Y., Lin, K., Mdlovu, N., Weng, M., Tsai, W., and Jeng, U. (2022). De novo synthesis of a MIL-125(Ti) carrier for thermal- and pH-responsive drug release. Biotechnol. Adv., 140.10.1016/j.bioadv.2022.213070 ↗
40. Kush, P., Kaur, M., Sharma, M., Madan, J., Kumar, P., Deep, A., and Kim, K. (2020). Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: Biodistribution, pharmacokinetic and cytotoxicity study. Biomed. Phys. Eng. Express, 6.10.1088/2057-1976/ab73f7 ↗
41. Highly Efficient Encapsulation of Doxorubicin Hydrochloride in Metal-Organic Frameworks for Synergistic Chemotherapy and Chemodynamic Therapy10.1021/acsbiomaterials.1c00874 ↗
42. MIL-125-based nanocarrier decorated with Palladium complex for targeted drug delivery10.1038/s41598-022-16058-w ↗
43. Improving the genistein oral bioavailability via its formulation into the metal-organic framework MIL-100(Fe)
44. Leng, X., Dong, X., Wang, W., Sai, N., Yang, C., You, L., Huang, H., Yin, X., and Ni, J. (2018). Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers. Molecules, 23.10.3390/molecules23102490 ↗
45. Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy10.1158/0008-5472.CAN-12-1076 ↗
46. Autophagy modulation as a potential targeted cancer therapy: From drug repurposing to new drug development10.1002/kjm2.12361 ↗
47. Relationship between Autophagy and Drug Resistance in Tumors10.2174/1389557522666220905090732 ↗
48. Autophagy and multidrug resistance in cancer
49. 3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy10.3109/1061186X.2014.936870 ↗
50. Cell Death Triggered by the Autophagy Inhibitory Drug 3-Methyladenine in Growing Conditions Proceeds With DNA Damage10.3389/fphar.2020.580343 ↗
51. A facile synthesis of uniform hollow MIL-125 titanium-based nanoplatform for endosomal esacpe and intracellular drug delivery10.1016/j.cej.2020.125246 ↗
52. Stimuli-responsive, dual-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance10.1016/j.actbio.2021.11.050 ↗